Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/2cls

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)

Bernstein Research

Geoffrey Porges

Upgrade

Outperform (from market perform)

1%

$155.12

Porges also raised his target to $193 from $188 after Alexion said 1Q14 sales of Soliris eculizumab, its sole product, rose 67% to $566.6M and topped the Street's estimate of $560.2M (see BioCentury, April 28). Alexion markets Soliris in almost 50 countries for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Last month, Alexion began two Phase III trials with Soliris to treat neuromyelitis optica and myasthenia gravis, which Porges said could offer real incremental revenue potential. The company also disclosed it began submitting a rolling BLA to FDA for asfotase alfa (ENB-0040) to treat hypophosphatasia (HPP).